A preliminary study of long-term treatment with interferon gamma-1b and lowdose prednisolone in patients with idiopathic pulmonary fibrosis 
Cryptogenic fibrosing alveolitis (CFA) is a restrictive currently therefore somewhere between 3500 and 17 000 patients with CFA, and physicians serving a lung disease that typically presents in patients in their late sixties with symptoms of breathlessness and cough. 1 population of 500 000 will have between 30 and 140 cases under their care. CFA is thus a major and life Although a small proportion of patients have relatively stable disease, the clinical course in the majority involves threatening problem for individual patients and is an appreciable burden to those who provide respiratory progressively disabling breathlessness, culminating in death from respiratory failure. 2 The median life exhealth services. One of the more frustrating aspects of the management of CFA that both patients and their pectancy of unselected newly diagnosed patients with CFA is of the order of three years, 3 a prognosis similar doctors have to face is the lack of clearly effective treatments for the disease, and a paucity of evidence to that of clinical stage Ib non-small cell lung cancer. 4 CFA is generally considered to be a rare disease but, from randomised, controlled clinical trials on which to determine how best to use the treatments that are depending on the stringency of diagnostic criteria used, probably occurs in somewhere between six and 28 available. The recent study by Ziesche and colleagues
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Britton patients with CFA treated with prednisolone plus inthe fact that in clinical practice, corticosteroids have been the mainstay of treatment for CFA for many terferon gamma-1b relative to prednisolone alone therefore provides an important new contribution to the years 1 8 9 14 15 on the grounds of evidence derived from a series of anecdotal reports and observational studies evidence base for the management of this disease. Their paper also poses interesting questions on the funding dating back to the mid 1950s. 15 However, the use of corticosteroids in CFA has never been subjected to a of treatment for CFA.
Current treatment for CFA consists of steroids, given randomised controlled clinical trial, and there is therefore no conclusive unbiased evidence that corticoeither alone or in combination with an immunosuppressant or cytotoxic agent.
1 8 9 The first line treatsteroids have any effect on either mortality or morbidity in this disease. 10 11 15 In the UK, however, corticosteroids ment for CFA recently recommended in guidelines produced by the British Thoracic Society (BTS) 10 and are given to 90% or more of patients who receive any active treatment for CFA, comprising the sole treatment in a consensus statement from the American Thoracic and European Respiratory Societies 11 is a combination in 76%, 1 and are also reported to be the most frequently used treatment for CFA in the USA.
8 9 The use of of prednisolone and either azathioprine or cyclophosphamide. The evidence supporting the use of corticosteroids to treat CFA is so established in conventional wisdom in Britain that in 1999 the Medical azathioprine comes primarily from a randomised, double blind, placebo controlled clinical trial in which Research Council cited concerns over the ethics of randomising patients to placebo as the major reason for 27 patients with chronic progressive CFA were randomised to receive either prednisone alone (13 patients), declining a proposal to conduct a randomised placebo controlled trial of corticosteroid therapy in CFA (Medor prednisone plus azathioprine (14 patients).
12 After one year of treatment mortality was similar with the ical Research Council, personal communication). Current management of CFA thus depends heavily on the two treatments, with four deaths in each group but, among the survivors, lung function had improved use of a treatment of no proven benefit, sometimes given in combination with one of two drugs that appear slightly but non-significantly more in the patients treated with azathioprine plus prednisone. The magnitude of to have influenced mortality in the longer term, but not morbidity or lung function in the shorter term. In this this effect was of the order of a 6.5% increase in mean percentage predicted forced vital capacity (FVC) in the context, the emergence of objective evidence of clinical improvement with interferon gamma-1b in patients parazathioprine plus prednisone group, compared with a 1.7% increase in the prednisone only group, but the ticipating in a randomised clinical trial 7 is a welcome development. variation around these means was high and the difference far from statistically significant (p=0.87). After As in the above trials of azathioprine and cyclophosphamide, Ziesche and colleagues assessed the effect one year of treatment therefore, this study had found no conclusive evidence that adding azathioprine to of interferon gamma-1b given as an addition to corticosteroid therapy. 7 The patients they selected appear to corticosteroids decreased mortality from CFA or influenced the clinical progress of the disease. The evibe broadly representative of those who would currently receive treatment in the UK -that is, those with evidence dence that has led to the use of this drug in the treatment of CFA is that, after a period of extended follow up to of progressive disease. 10 The entry criteria for their study were histologically confirmed idiopathic pulmonary fiba total of nine years after randomisation, deaths in the azathioprine plus prednisone group had increased to six rosis (an alternative term for CFA), a decline in lung function of at least 10% in the preceding 12 months and in the prednisone group to 10. With adjustment for age this difference was on the borderline of statistical despite continuous or repeated glucocorticoid therapy, and a total lung capacity above 45% of the predicted significance, which leads to the conclusion that azathioprine may reduce longer term mortality from CFA.
value. The main criteria used to define the histological diagnosis was the presence of subpleural and periacinar Azathioprine appeared to be well tolerated in this study, the majority of adverse effects being attributed to predfibrosis, with only minor cellular infiltration. All patients meeting these criteria then received four weeks of high nisone.
The evidence for the use of cyclophosphamide arises dose (50 mg/day) prednisolone, reducing to 10 mg/day over the next two weeks. Patients in whom this period from an earlier randomised controlled trial in which mortality at three years was significantly reduced in 21 of treatment was deemed ineffective were then randomised to receive either 200 g of interferon gammapatients with CFA receiving prednisolone plus cyclophosphamide (three deaths) compared with 22 patients 1b subcutaneously three times per week in addition to 7.5 mg of oral prednisolone per day, or to prednisolone receiving prednisolone alone (10 deaths).
13 Details of changes in lung function were not presented in this alone, in an open study. Treatment was continued for one year; the only difference in the treatments paper but clinical improvement defined in terms of change in one or more of symptom scores, chest radioadministered during that time was that, in the corticosteroid only group, the dose of corticosteroids could be graphic appearances, or lung function tests occurred at any stage of the three year follow up in seven patients increased to up to 50 mg/day in those with deterioration in lung function or worsening symptoms. receiving prednisolone only and in five patients receiving prednisolone plus cyclophosphamide. As with azAlthough the paper does not tell us which measure or measures of lung function were required to have athioprine, therefore, the evidence supporting the use of cyclophosphamide in CFA is the significant effect on declined by 10% in the 12 months prior to recruitment, and does not define ineffectiveness in relation to the mortality, not on symptoms or lung function. Unlike azathioprine, cyclophosphamide was associated with a one month period of high dose corticosteroid treatment immediately before randomisation, the impression preclinically appreciable increase in the occurrence of adverse effects, primarily haematological toxicity, which sented is that these patients had relatively established fibrotic disease that was deteriorating on usual steroid occurred in approximately one in three patients.
The design of both of these clinical trials involved therapy. The authors report that all of the patients had a histological diagnosis of usual interstitial pneumonia the placebo controlled assessment of a drug given in addition to corticosteroids, and did not include a (UIP), and the histological and high resolution computerised tomographic criteria given in the paper are placebo control for corticosteroid therapy. This reflects group.bmj.com on October 13, 2017 -Published by http://thorax.bmj.com/ Downloaded from Interferon gamma-1b therapy for cryptogenic fibrosing alveolitis S39 consistent with this diagnosis. 16 UIP is the commonest gamma-1b should also be assessed in relation to other currently used treatments, particularly azathioprine and histological subtype of CFA and is recognised to be chronically progressive, unresponsive to treatment, and cyclophosphamide, again providing an opportunity to investigate in more detail the contribution that these usually fatal. 16 The active and progressive nature of the disease in these patients in the presence of usual drugs make, either alone or in combination with corticosteroids. Even if only some of these studies are carried treatment is further evident from the subsequent 12 month experience in the prednisolone only treatment out, then one major positive effect of the work of Ziesche and colleagues 7 will have been to cause these questions group, in which total lung capacity (TLC) decreased in all patients by an average of 4% of the predicted value, to be addressed. However, their study is also likely to stimulate interest in other putative treatments for CFA and partial pressure of oxygen at rest and after exercise decreased in all but one patient. However, in the patients since they have presented evidence that the likely mechanism of the effect of interferon gamma-1b was a rereceiving interferon gamma-1b all of these measures of lung function increased during the treatment period duction in transcription of genes for the production of transforming growth factor 1 and connective tissue to an extent that was significant within the group and in comparison with the prednisolone only growth factor. 7 This observation is likely to provide a major stimulus to investigate and develop other agents group (p<0.001 for all between group comparisons). The magnitude of the within group increase in TLC in that can influence the production of these and related growth factors, and progress in this area is likely to be the interferon gamma-1b group was an average of 9% predicted, with a mean difference in change between relevant to many disorders in addition to CFA. This, in turn, raises the prospect that CFA and related diseases groups of 13% predicted. Effects of similar magnitude on change in FVC and carbon monoxide gas transfer may become a more economically viable target for investment in pharmaceutical research and developwere also reported, but numerical details were not provided in the paper. There were no deaths amongst ment, which would indeed be a major step forward for CFA and perhaps some of the other "orphan" diseases the patients taking part in the study and no formal quality of life measures were made. However, breathin respiratory and other fields of medicine. There is, however, one very important and much lessness and the ability to carry out activities of daily living at the end of the study were markedly improved more immediate practical question that arises from the work of Ziesche et al, and this is whether, in clinical in the patients who received interferon gamma-1b, indicating that the improvement in lung function measures practice, patients with CFA should now be treated with interferon gamma-1b. Since the available clinical trial was associated with improvement in symptoms and disability.
evidence indicates that interferon gamma-1b is clinically effective in this disease, and in terms of improvement These findings are remarkable on at least two counts. Firstly, they provide evidence that drug treatment resin lung function, breathlessness and related morbidity appears to have more to offer in typical patients with ulted in statistically and clinically significant improvement in lung function and morbidity in patients CFA than either azathioprine or cyclophosphamide, the logical conclusion is that they should, at least until such with CFA. No other treatment has been shown to do this in the context of a randomised, controlled clinical time as evidence emerges to the contrary. Indeed, it can be argued that both cyclophosphamide and azathioprine trial. Secondly, the improvement in the group receiving interferon gamma-1b was remarkably consistent across are currently used on the grounds of evidence of efficacy that is no more persuasive than that now available all outcome measures. All of the patients who received interferon gamma-1b were better at the end of the for interferon gamma-1b. Is there any justification for withholding a treatment that was associated with "subtreatment period, whilst nearly all of the prednisolone only group were worse. No other study, randomised or stantial improvements" in pulmonary ventilation and gas exchange 7 from patients currently suffering from otherwise, has reported such consistent improvement within a prospectively defined group of patients. The CFA? In a covering editorial published alongside the study was small, involving only 18 patients in all, and did not include a double blind placebo control for the paper, du Bois argued that the findings of pilot studies, however promising, cannot be used as the basis of interferon gamma-1b but, in the light of the consistency and high degree of statistical significance of the differrecommendations for treatment, and in support of this argument cited various concerns relating to the repences between the treatment groups, the overwhelming implication of these data is that treatment with interferon resentativeness of the patients in this study relative to patients with CFA in general. 18 Whilst commendable, gamma-1b was effective in these patients. This in itself is an exciting and potentially very fruitful however, and not disputing the importance of independent confirmation, it is evident that this argument advance in current management options. As with any therapeutic development, it is important that the findhas not discouraged either the widespread use or the adoption into clinical management guidelines of either ings of this study are independently confirmed, either in a repeat study of similar design or in the context of azathioprine or cyclophosphamide, 10 11 in both cases on the grounds of single clinical trials involving small a broader clinical trial, and the longer term effects of interferon gamma-1b on morbidity and mortality sample sizes and producing no evidence of substantial improvement in ventilation or gas exchange. 12 13 It is assessed. It is also important that the contribution of prednisolone in this therapeutic combination is tested therefore arguable that, if the role of interferon gamma1b needs to be independently confirmed before it is to determine whether the beneficial effect of interferon gamma-1b is the same, greater, or less in the absence used to treat patients, then so should the roles of azathioprine and cyclophosphamide and, for that matof prednisolone. It will also be necessary to determine whether the effect of interferon gamma-1b is in fact ter, corticosteroids. Caveats relating to the representativeness of the patients in this study to the general attributable to the negation of potential adverse effects of prednisolone on the natural history of CFA, 17 and population of patients with CFA are also important, but the simple solution to these concerns that is widely this will involve a placebo controlled trial which might in turn establish, at long last, whether corticosteroids applied in implementing clinical trial evidence in many areas of medicine is to define the indications for are indeed effective in CFA. The effect of interferon
